Table 2.
Baseline characteristics between ICIs combined with chemotherapy group and chemotherapy alone group
| Characteristics | ICIs + chemotherapy n = 129 |
Chemotherapy n = 80 |
P value |
|---|---|---|---|
| Combine with ICIs | Yes | No | < 0.001 |
| Gender | 0.082 | ||
| Male | 81 (62.8) | 42 (52.5) | |
| Female | 48 (37.2) | 38 (47.5) | |
| Age (years) | 60.12 ± 8.99 | 60 ± 9.33 | 0.061 |
| < 60 | 59 (45.7) | 38(47.5) | |
| ≥ 60 | 70 (54.3) | 42 (52.5) | |
| Smoking or drinking | 0.124 | ||
| Yes | 68 (52.7) | 34 (42.5) | |
| No | 61 (47.3) | 46(57.5) | |
| Tumor location | 0.077 | ||
| ICC | 61 (47.3) | 34(42.4) | |
| HCCA | 25 (19.8) | 16(20.0) | |
| DCCA | 18 (13.1) | 15(18.8) | |
| GCA | 25 (19.8) | 15 (18.8) | |
| Tumor differentiation | 0.042 | ||
| Well | 7 (5.4) | 4(5.0) | |
| Moderately | 37 (28.7) | 21 (26.3) | |
| Poorly | 36 (27.9) | 23 (28.8) | |
| Unknown | 49 (38.0) | 32 (39.9) | |
| Serum albumin | 0.100 | ||
| < 36 g/L | 77 (59.7) | 44(55.0) | |
| ≥ 36 g/L | 52 (40.3) | 36(45.0) | |
| Liver metastasis | 0.055 | ||
| Yes | 81 (62.8) | 42 (52.5) | |
| No | 48 (37.2) | 38 (47.5) | |
| Multi-site metastasis | 0.031 | ||
| Yes | 77 (59.7) | 43 (53.8) | |
| No | 52 (40.3) | 37(46.2) | |
| Response | 0.042 | ||
| CR | 10 (7.8) | 1 (1.3) | |
| PR | 41 (31.8) | 21(26.3) | |
| SD | 65 (50.4) | 45 (56.3) | |
| PD | 13 (10.0) | 13 (16.1) | |
| NLR | 0.021 | ||
| < 3.0 | 57 (44.2) | 37 (46.3) | |
| ≥ 3.0 | 72 (55.8) | 43 (53.7) | |
| PLR | 0.032 | ||
| < 160 | 58 (45.0) | 35(43.8) | |
| ≥ 160 | 71 (55.0) | 45(56.2) | |
| Total bilirubin | 0.103 | ||
| < 21umol/L | 34 (26.4) | 29 (36.6) | |
| ≥ 21umol/L | 95 (73.6) | 51(63.4) | |
| ALT | 0.241 | ||
| < 50U/mL | 61 (47.3) | 41 (51.3) | |
| ≥ 50U/mL | 68 (52.7) | 39(48.7) | |
| CA19-9 | 0.002 | ||
| < 37U/mL | 42 (32.6) | 30(37.5) | |
| ≥ 37U/mL | 87 (67.4) | 50(62.5) | |
| AST | 0.334 | ||
| < 40U/mL | 48 (37.2) | 32(40.0) | |
| ≥ 40U/mL | 81 (62.8) | 48(60.0) | |
| MLR | 0.007 | ||
| < 2.3 | 60 (46.5) | 33(41.3) | |
| ≥ 2.3 | 69 (53.5) | 47(58.7) | |
| SII | 0.015 | ||
| < 830.06 | 58 (45.0) | 29(36.3) | |
| ≥ 830.06 | 71 (55.0) | 51 (63.7) | |
| CONUT score | 0.144 | ||
| < 2 | 59 (45.7) | 34 (42.5) | |
| ≥ 2 | 70 (54.3) | 46(57.5) |
ICCA intrahepatic cholangiocarcinoma; HCCA hilar cholangiocarcinoma; DCCA distal cholangiocarcinoma; GCA gallbladder carcinoma; NLR neutrophil-to-lymphocyte ratio; PLR platelet-to-lymphocyte ratio; MLR monocyte-to-lymphocyte ratio; SII systemic inflammatory index (SII was calculated by multiplying the platelet count by the neutrophil count divided by the lymphocyte count); ALT alanine transaminase; AST aspartate transaminase; CA19-9 glycoprotein antigen 19-9; CONUT score controlling nutritional status score